These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36439029)

  • 1. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.
    Grabherr F; Grander C; Effenberger M; Schwärzler J; Tilg H
    Ther Adv Endocrinol Metab; 2022; 13():20420188221139101. PubMed ID: 36439029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.
    Kulkarni AV; Sarin SK
    Ther Adv Endocrinol Metab; 2023; 14():20420188231178370. PubMed ID: 37323163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
    Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
    Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
    Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Apr; ():. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
    Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
    Fouad Y; Palmer M; Chen M; Regev A; Banerjee R; Myers R; Riccio R; Torstenson R; Younes R; Arora PS; Landgren H; Karsdal MA; Blake M; Shapiro DA; Gruss HJ; Sheikh MY; Attia D; Bollipo S; Smith AD; Freilich B; Gish RG; Schuppan D
    J Clin Transl Hepatol; 2022 Apr; 10(2):374-382. PubMed ID: 35528969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations.
    Xu X; Zhou X; Tian T; Ding Y; Yu C; Zhao W; Wang X; Lu J; Guo W; Jiang L; Wang Q; Zhang Q; Song C
    J Clin Transl Hepatol; 2023 Aug; 11(4):777-786. PubMed ID: 37408819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.